-
K A van Nifterik,
J van den Berg,
W F van der Meide, N Ameziane,
L E Wedekind,
R D M Steenbergen,
S Leenstra,
M V M Lafleur,
B J Slotman,
L J A Stalpers,
P Sminia
[show abstract]
[hide abstract]
ABSTRACT: The DNA repair protein O(6)-methylguanine-DNA methyltransferase (MGMT) can cause resistance to the alkylating drug temozolomide (TMZ). The purpose of this study was to determine the relationship between the MGMT status, determined by means of several techniques and methods, and the cytotoxic response to TMZ in 11 glioblastoma multiforme (GBM) cell lines and 5 human tumour cell lines of other origins.
Cell survival was analysed by clonogenic assay. The MGMT protein levels were assessed by western blot analysis. The MGMT promoter methylation levels were determined using methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) and quantitative real-time methylation-specific PCR (qMSP). On the basis of the results of these techniques, six GBM cell lines were selected and subjected to bisulphite sequencing.
The MGMT protein was detected in all TMZ-resistant cell lines, whereas no MGMT protein could be detected in cell lines that were TMZ sensitive. The MS-MLPA results were able to predict TMZ sensitivity in 9 out of 16 cell lines (56%). The qMSP results matched well with TMZ sensitivity in 11 out of 12 (92%) glioma cell lines. In addition, methylation as detected by bisulphite sequencing seemed to be predictive of TMZ sensitivity in all six cell lines analysed (100%).
The MGMT protein expression more than MGMT promoter methylation status predicts the response to TMZ in human tumour cell lines.
British Journal of Cancer 06/2010; 103(1):29-35. · 5.04 Impact Factor
-
C J Hess, N Ameziane,
G J Schuurhuis,
A Errami,
F Denkers,
G J L Kaspers,
J Cloos,
H Joenje,
D Reinhardt,
G J Ossenkoppele,
C M Zwaan,
Q Waisfisz
[show abstract]
[hide abstract]
ABSTRACT: Inactivation of the FA-BRCA pathway results in chromosomal instability. Fanconi anaemia (FA) patients have an inherited defect in this pathway and are strongly predisposed to the development of acute myeloid leukaemia (AML). Studies in sporadic cancers have shown promoter methylation of the FANCF gene in a significant proportion of various solid tumours. However, only a single leukaemic case with methylation of one of the FA-BRCA genes has been described to date, i.e. methylation of FANCF in cell line CHRF-288. We investigated the presence of aberrant methylation in 11 FA-BRCA genes in sporadic cases of leukaemia.
We analyzed promoter methylation in 143 AML bone marrow samples and 97 acute lymphoblastic leukaemia (ALL) samples using methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA). Samples with aberrant methylation were further analyzed by bisulphite sequencing and tested for mitomycin C sensitivity using Colony Forming Units assays.
MS-MLPA showed promoter methylation of FANCC in one AML and three ALL samples, while FANCL was found methylated in one ALL sample. Bisulphite sequencing of promoter regions confirmed hypermethylation in all cases. In addition, samples with hypermethylation of either FANCC or FANCL appeared more sensitive towards mitomycin C in Colony Forming Units assays, compared to controls.
Hypermethylation of promoter regions from FA-BRCA genes does occur in sporadic leukaemia, albeit infrequently. Hypermethylation was found to result in hypersensitivity towards DNA cross-linking agents, a hallmark of the FA cellular phenotype, suggesting that these samples displayed chromosomal instability. This instability may have contributed to the occurrence of the leukaemia. In addition, this is the first report to describe hypermethylation of FANCC and FANCL. This warrants the investigation of multiple FA-BRCA genes in other malignancies.
Cellular oncology: the official journal of the International Society for Cellular Oncology 02/2008; 30(4):299-306. · 4.17 Impact Factor
-
C.J. Hess, N. Ameziane,
G.J. Schuurhuis,
A. Errami,
F. Denkers,
I. Hubeeck,
G.J.L. Kaspers,
H. Joenje,
D. Reinhardt,
G.J. Ossenkoppele,
C.M. Zwaan,
Q. Waisfisz
[show abstract]
[hide abstract]
ABSTRACT: Times Cited: 1
Meeting Abstract
English
2224
Cited References Count: 0
111GS
1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
WASHINGTON
Part 1
Blood 11/2006; 108(11):630A. · 9.90 Impact Factor
